Appointment of Catherine Moukheibir to Board of Ablynx
The meeting of the Board of Directors on 20th August approved the appointment of Catherine Moukheibir as an Independent Director of the Company. Catherine is a seasoned finance executive with 20 years of international experience at senior levels in major investment banks and as a C-level executive in listed and private biotech companies across Europe. She is currently a member of the Executive Board of Innate Pharma and an Independent Director of Creabilis.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis, Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
Posted: August 2013